COVID-19 is a respiratory disease caused by a new coronavirus (SARS-CoV-2) and causes significant morbidity and mortality. This study is a retrospective trial to assess the efficacy of Remdesivir in adult patients diagnosed with COVID-19 in Mansoura University Isolation Hospital. In this study the investigators will analyze the data collected during treatment.
COVID-19 is a novel respiratory disease caused by coronavirus (SARS-CoV-2) and results in
significant morbidity and mortality. To date there is no approved medication for the
treatment of patients with COVID-19. Remdesivir is a broad-spectrum antiviral nucleotide
analogue that inhibits RNA-dependent RNA polymerase activity among a diverse group of RNA
viruses. Non-clinical and clinical data suggest that Remdesivir may be useful for the
treatment of COVID-19. WHO has identified Remdesivir as a candidate drug of interest to be
studied in clinical trials. This retrospective study is designed to analyze the data
collected during the routine care of patients who have benefited from this therapy.
Drug: Remdesivir
This study is a retrospective trial to assess the efficacy of Remdesivir in adult patients diagnosed with COVID-19 in Mansoura University Isolation Hospital. In this study we will analyze the data collected during treatment.
Inclusion Criteria:
1. Adult ≥ 18 years old.
2. SARS-CoV-2 infection confirmed.
3. Patients having classical radiological lesions of COVID-19 on X-ray chest or HRCT
chest.
4. Hospitalized patients who received at least one administration of Remdesivir therapy
(Dose: 200mg day one then 100mg daily for up to 10 days).
Exclusion Criteria:
1. Presences of chronic renal failure > 4 stage, GFR < 30ml/min.
2. ALT/AST > 5 times than normal values.
3. Pregnant women.
Mansoura University Hospital
Mansoura, Dakahliya, Egypt
Investigator: El Sharawy Kamal, Professor
Contact: 002 050 2202876
muh@mans.edu.eg
Investigator: